Translational Challenges in 3D-Bioprinting

By Prasad Shastri, Professor of Biofunctional Macromolecular Chemistry & Bioss Professor of Cell Signalling Environments / Director, Institute for Macromolecular Chemistry at University of Freiburg

3D-Bioprinting holds much promise in advancing medicine as tool to replicate cellular complexity of tissue environment ex vivo for drug screening and as a means of engineering well-defined functional tissue units for transplantation. In regards to the latter, 3D-bioprinting offers a critical link between principles of tissue engineering and patient-specific delivery of healthcare.

This potential, hinges on the ability to develop a clinically and commercially viable translation pipeline. This presentation will highlight and discuss the challenges associated with translation of 3D-bioprinting into the clinic and perceived bottlenecks and make a case of the development of a standardization platform/metrics for 3D-bioprinting.

Click here for the complete conference program.


Question 1: What drives you?
The rush involved in a discovery and the ability to make quantifiable impact on peoples lives

Question 2: Why should the delegate attend your presentation?
To hear how 3D-bioprinting landscape need to evolve if it has to be successful and impactful as a technology and a research field

Question 3: What emerging technologies/trends do you see as having the greatest potential in the short and long run?
Several: in addition to 3D-bioprinting, genomics, synthetic biology, optogenetics, metabolomics, adaptive and smart biomaterials, wearables ad smart textiles.

Question 4: What kind of impact do you expect them to have?
Early days , so one has to wait and see.

Question 5: What are the barriers that might stand in the way?
Will to implement, cost, insurance reimbursement and perceived risks or ethical issues.

About Prasad Shastri
Prasad Shastri is the Professor of Biofunctional Macromolecular Chemistry and the Director of the Institute for Macromolecular Chemistry at the University of Freiburg. He is also a core faculty of the DFG funded BIOSS excellence cluster where he holds the position of Professor of Cell Signalling Environments. He received his Ph.D. from Rensselaer Polytechnic Institute (USA) and carried out his post-doctoral work with Prof. Langer at MIT. He has published over 120 peer-reviewed papers and authored several proceedings, extended abstracts and over 50 issued and pending patents. His laboratory is active in the area of biomaterials, mechanobiology, 3D-bioprinting, intracellular delivery of nanomaterials, cancer biology, functional imaging and in vivo engineering of tissue and made several notable contributions in materials science and biology and pioneered the “in vivo bioreactor” paradigm for de novo engineering bone and cartilage tissue.

Leave a Reply

Your email address will not be published.